CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
ipratropium bromide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01691079
NCT01691079Phase 4Completed
CompareCT.gov

Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes

University of California, San Francisco·interventional·Posted Sep 24, 2012·Updated Jun 5, 2020

In Brief

A Phase 4 clinical trial evaluating ipratropium bromide and Placebo for Bronchospasm, Exercise-Induced. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This will be a double-blind placebo-controlled study in which we plan to study 40 competitive endurance athletes. We will conduct an exercise test to evaluate maximal oxygen uptake and 2 exercise challenge tests to provoke EIA. Prior to the exercise challenge tests the athletes will randomly receive inhaled placebo or inhaled ipratropium bromide. We will compare the athletes' airway response to the exercise challenge with and without the active drug.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBronchospasm, Exercise-Induced
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 24, 2012
Enrollment StartDec 1, 2012
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 13.8 years ago

Interventions

ipratropium bromidedrug

Inhaled ipratropium bromide administered before exercise.

Placebodrug

Inhaled placebo administered before exercise.